Breaking Finance News

Allergan (NYSE:AGN) stock price target reduced to $300 as reported today by RBC Capital

Indicating a possible upside of 0.21%, RBC Capital dropped the target price of Allergan (NYSE:AGN) to $300

On 8/05/2016, Mizuho Securities released a statement on Allergan(NYSE:AGN) suggesting “Neutral” with a target price of $246. At the time, this suggested a downside of -0.03%.

Yesterday Allergan (NYSE:AGN) traded 2.18% lower at $248.31. AGN’s 50-day average is $241.80 and its 200-day moving average is $251.74. The last stock price close is down 1.36% relative to the 200-day moving average, compared with the S&P 500 which has increased 0.00% over the date range. Volume of trade was was up over the average, with 6,691,438 shares of AGN changing hands over the typical 3,463,230 shares..

Performance Chart:

Allergan (NYSE:AGN)

With a total market value of $98.2B, Allergan has a one-year low of $195.50 and a 52 week high of $325.00 with a price-earnings ratio of 22.

Also covering Allergan’s target price, a total of 16 brokers have reported on the company. The average target is $293.75 with seven analysts rating the company a strong buy, 11 analysts rating the company a buy, two firms rating the stock a hold, zero rating the stock to underperform, and lastly zero analystsrating the stock as sell.

Brief Synopsis About Allergan (NYSE:AGN)

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.